UltraSPECT, a provider of nuclear medicine (NM) image reconstruction technology, has reached a distribution agreement with PharmaLogic for the sale of UltraSPECT’s Cardiac and Bone imaging applications. The agreement will enable PharmaLogic to provide its hospitals and imaging centers with access to UltraSPECT’s Xpress line of products for significantly lower radiation dose with no diminished image quality.
Through the use of UltraSPECT’s Wide-Beam Reconstruction (WBR) technology, the products in the company’s growing portfolio of solutions can provide two unique advantages. They significantly reduce the standard radiopharmaceutical dose requirements for cardiac and bone nuclear medicine imaging exams and/or cut the imaging procedure time in half while maintaining the image quality the facility is accustomed to, and many times even enhancing the image resolution.
For more information visit: www.ultraspect.com.
